Non-Proliferative Diabetic Retinopathy (NPDR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Pages: 40 Published: May 04, 2022 Report Code: GMDGDHC2595IDBOD

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    https://www.ispeech.org/text.to.speech

Non-Proliferative Diabetic Retinopathy (NPDR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Non-Proliferative Diabetic Retinopathy (NPDR) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Proliferative Diabetic Retinopathy (NPDR), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Proliferative Diabetic Retinopathy (NPDR).

– The pipeline guide reviews pipeline therapeutics for Non-Proliferative Diabetic Retinopathy (NPDR) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Non-Proliferative Diabetic Retinopathy (NPDR) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Non-Proliferative Diabetic Retinopathy (NPDR) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Non-Proliferative Diabetic Retinopathy (NPDR).

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Non-Proliferative Diabetic Retinopathy (NPDR).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Non-Proliferative Diabetic Retinopathy (NPDR) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Report Coverage

Indication – Overview

Indication – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Indication – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Indication – Companies Involved in Therapeutics Development

Company 1

Company 2

Company 3

Company XX

Indication – Drug Profiles

Drug 1 – Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug 2 – Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug 3 – Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug 4 – Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug XX – Drug Profile

Product Description

Mechanism of Action

R&D Progress

Indication – Dormant Projects

Indication – Discontinued Products

Indication – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Indication, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Indication – Pipeline by Company 1, 2022

Indication – Pipeline by Company 2, 2022

Indication – Pipeline by Company 3, 2022

Indication – Pipeline by Company XX, 2022

Indication – Dormant Projects, 2022

Indication – Discontinued Products, 2022

List of Figures

Number of Products under Development for Indication, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.